Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
Spero Therapeutics reports 2019 executive compensation
By ExecPay News
Published: September 30, 2020
Spero Therapeutics reported fiscal year 2019 executive compensation information on September 30, 2020.
In 2019, three executives at Spero Therapeutics received on average a compensation package of $1.2M, a 43% increase compared to previous year.
Average pay of disclosed executives at Spero Therapeutics
Ankit Mahadevia, Chief Executive Officer, received $1.8M in total, which increased by 148% compared to 2018. 42% of Mahadevia's compensation, or $753K, was in option awards. Mahadevia also received $250K in non-equity incentive plan, $497K in salary, $285K in stock awards, as well as $792 in other compensation.
Christina Larkin, Chief Operating Officer, received a compensation package of $943K, which increased by 77% compared to previous year. 42% of the compensation package, or $394K, was in salary.
David Melnick, Chief Medical Officer, earned $936K in 2019, a 43% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on September 30, 2020.